Mayumi Kawabe, Ph.D.

2009 University of Pittsburgh, Pittsburgh, PA, United States 
"Mayumi Kawabe"


Sign in to add mentor
Walter J. Storkus grad student 2009 University of Pittsburgh
 (Developing combinational immunotherapies targeting tumor receptor tyrosine kinases.)
BETA: Related publications


You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Rao A, Taylor JL, Chi-Sabins N, et al. (2012) Combination therapy with HSP90 inhibitor 17-DMAG reconditions the tumor microenvironment to improve recruitment of therapeutic T cells. Cancer Research. 72: 3196-206
Rao A, Kawabe M, Storkus WJ. (2012) Abstract 4399: Immunostimulatory effects of HSP90 inhibition: Insights from combinational immunotherapies targeting EphA2 Cancer Research. 72: 4399-4399
Zhao X, Bose A, Komita H, et al. (2011) Intratumoral IL-12 gene therapy results in the crosspriming of Tc1 cells reactive against tumor-associated stromal antigens. Molecular Therapy : the Journal of the American Society of Gene Therapy. 19: 805-14
Rao A, Kawabe M, Storkus WJ. (2011) Abstract 1805: Integration of 17-(Dimethylaminoethylamino)-17-demethoxygeldanamycin (17-DMAG) in combinational immunotherapy targeting tumor antigen EphA2 Cancer Research. 71: 1805-1805
Kawabe M, Mandic M, Taylor JL, et al. (2009) Heat shock protein 90 inhibitor 17-dimethylaminoethylamino-17-demethoxygeldanamycin enhances EphA2+ tumor cell recognition by specific CD8+ T cells. Cancer Research. 69: 6995-7003
Komita H, Zhao X, Katakam AK, et al. (2009) Conditional interleukin-12 gene therapy promotes safe and effective antitumor immunity. Cancer Gene Therapy. 16: 883-91
Wesa AK, Herrem CJ, Mandic M, et al. (2008) Enhancement in specific CD8+ T cell recognition of EphA2+ tumors in vitro and in vivo after treatment with ligand agonists. Journal of Immunology (Baltimore, Md. : 1950). 181: 7721-7
Storkus WJ, Herrem C, Kawabe M, et al. (2007) Improving immunotherapy by conditionally enhancing MHC class I presentation of tumor antigen-derived Peptide epitopes. Critical Reviews in Immunology. 27: 485-93
See more...